Stephen Basso
Director of Finance/CFO bei INNOVIVA, INC.
Vermögen: 184 343 $ am 31.03.2024
Profil
Stephen Basso is currently the Chief Financial Officer at Innoviva, Inc. Prior to this, he was the Vice President-North America Commercial at Alexion Pharmaceuticals, Inc. from 2016 to 2017, and the Chief Financial Officer & Senior VP-Finance at Inozyme Pharma, Inc. from 2020 to 2021.
He also served as the Chief Operating & Financial Officer at Cybrexa, Inc. Mr. Basso holds an MBA from Boston College and an undergraduate degree from Providence College.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INNOVIVA, INC.
0,02% | 05.03.2024 | 12 096 ( 0,02% ) | 184 343 $ | 31.03.2024 |
Aktive Positionen von Stephen Basso
| Unternehmen | Position | Beginn |
|---|---|---|
| INNOVIVA, INC. | Director of Finance/CFO | 21.08.2023 |
Ehemalige bekannte Positionen von Stephen Basso
| Unternehmen | Position | Ende |
|---|---|---|
| INOZYME PHARMA, INC. | Director of Finance/CFO | 14.05.2021 |
| ALEXION PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01.05.2017 |
Cybrexa, Inc.
 Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Director of Finance/CFO | - |
Ausbildung von Stephen Basso
| Boston College | Masters Business Admin |
| Providence College | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| INNOVIVA, INC. | Health Technology |
| INOZYME PHARMA, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Alexion Pharmaceuticals, Inc. engages in the business of serving patients and families affected by rare diseases and devastating conditions through the discovery, development, and commercialization of life-changing medicines. The firm also focuses on the development of haematology, nephrology, neurology, metabolic disorders, cardiology, and ophthalmology. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto, and Leonard Bell in January 1992 and is headquartered in Boston, MA. | Health Technology |
Cybrexa, Inc.
Cybrexa, Inc. BiotechnologyHealth Technology Cybrexa, Inc. develops molecule DNA repair inhibitors that directly target the tumor microenvironment. It develops and commercializes technologies that enables to improve cancer therapeutics. The company was founded by Per J. Hellsund, F. Kevin Didden, Ranjit S. Bindra, and Peter Glazer in 2016 and is headquartered in New Haven, CT. | Health Technology |
